Nasdaq exas.

Find the latest SEC Filings data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.Fintel reports that on May 5, 2023, UBS initiated coverage of Exact Sciences (NASDAQ:EXAS) with a Neutral recommendation.. Analyst Price Forecast Suggests 18.36% Upside. As of April 24, 2023, the ...Find the latest Financials data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.WebExact Sciences Corporation (NASDAQ:EXAS) has a market capitalization of $11.574 billion. Artisan Small Cap Fund made the following comment about Exact …Web

Dec 4, 2023 · Exact Sciences (NASDAQ:EXAS) has a recorded net income of -$623.51 million. EXAS has generated -$1.59 earnings per share over the last four quarters. What is Exact Sciences's EPS forecast for next year?

Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt Oct 04. Price target increased by 7.0% to US$109 Sep 19. Exact Sciences Corporation (NasdaqCM:EXAS) agreed to acquire Resolution Bioscience, Inc. from Agilent Technologies, Inc. (NYSE:A). Sep 13. Executive VP & CFO notifies of intention to sell stock

Exact Sciences world-class team is the driving force behind the most innovative growth engine in cancer diagnostics. Our scientists are using advanced technologies to harness the power of DNA, RNA ...First on this list of millionaire-maker stocks is Exact Sciences (NASDAQ :EXAS ), an exciting company in the world of cancer research. Exact Sciences has developed one highly successful cancer ..."Exact Sciences Corporation (NASDAQ:EXAS) is a cancer diagnostics company whose flagship product is Cologuard, a stool-based screening test for colon cancer. The stock declined because financial ...Exact Sciences Company Info. EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non ...

Turning to the calls side of the option chain, the call contract at the $51.00 strike price has a current bid of $3.30. If an investor was to purchase shares of EXAS stock at the current price ...

First on this list of millionaire-maker stocks is Exact Sciences (NASDAQ :EXAS ), an exciting company in the world of cancer research. Exact Sciences has developed one highly successful cancer ...

Find the latest analyst research for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.As of February 10, 2023, the average one-year price target for EXACT Sciences is $66.64. The forecasts range from a low of $35.35 to a high of $99.75. The average price target represents an ...Nov 25, 2023 · Exact Sciences (NASDAQ:EXAS) produces and sells diagnostic and cancer screening tests. The company is best known for its Cologuard product. That said, Exact Sciences has several other revenue ... Published. May 23, 2022 11:22AM EDT. Exact Sciences Corporation EXAS is well-poised for growth, backed by impressive first-quarter 2022 results. Further, the company’s legacy Screening business ...EXACT SCIENCES CORP ( EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...

EXACT Sciences Corporation stock price (EXAS) NASDAQ: EXAS. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert EXACT Sciences Corporation stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.Nov 17, 2023 · Close $61.17 Key Data Bid Price and Ask Price The bid & ask refers to the price that an investor is willing to buy or sell a stock. The bid is the highest amount that a buyer is currently willing... First on this list of millionaire-maker stocks is Exact Sciences (NASDAQ :EXAS ), an exciting company in the world of cancer research. Exact Sciences has developed one highly successful cancer ...The last time Exact Sciences (NASDAQ: EXAS) announced its quarterly results, revenue increased 64% compared with the prior-year period. It was a different story on the company's bottom line ...Posted by Defense World Staff on Nov 1st, 2023. Exact Sciences Co. ( NASDAQ:EXAS – Get Free Report) saw a large growth in short interest during the month of October. As of October 15th, there ...EXAS stock, on the other hand, ended the regular session at 51.92, up 16.4%. ... *Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade prices are not sourced from all markets.

NASDAQ: EXAS Exact Sciences. Market Cap. $12B. Today's Change (4.73%) $3.03. ... 10 stocks we like better than Exact Sciences When o ur analyst team has a stock tip, ...

Webull offers EXAS Ent Holdg (EXAS) historical stock prices, in-depth market analysis, NASDAQ: EXAS real-time stock quote data, in-depth charts, free EXAS options chain data, and a fully built financial calendar to help you invest smart. Buy EXAS stock at Webull.A market research report on Exact Sciences ( NASDAQ: EXAS) from Cathie Wood's ARK-Invest ( ARKK) ( ARKG) has caught a lot of attention with another assertive call on the share price performance in ..."Exact Sciences Corporation (NASDAQ:EXAS) is a cancer diagnostics company whose flagship product is Cologuard, a stool-based screening test for colon cancer. The stock declined because financial ...In trading on Monday, shares of EXACT Sciences Corp. (Symbol: EXAS) entered into oversold territory, hitting an RSI reading of 28.7, after changing hands as low as $34.839 per share. By comparison ...Research Exact Sciences' (Nasdaq:EXAS) stock key valuation metrics while comparing it with its industry peers & market side by side. Dashboard Markets Discover Watchlist Portfolios Screener. Exact Sciences Corporation. ... What is EXAS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's ...Nasdaq 14,305.03 +78.81(+0.55%) Russell 2000 1,859.47 +50.45(+2.79%) Crude Oil 74.22 -1.74(-2.29%) Gold 2,089.80 +32.60(+1.58%) Advertisement Exact Sciences Corporation …WebAug 28, 2023 · One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was -16.81%, and its shares gained 127.30% of their value over the last 52 weeks. Exact Sciences Corporation (NASDAQ:EXAS) has a market ... "Exact Sciences Corporation (NASDAQ:EXAS) is a cancer diagnostics company whose flagship product is Cologuard, a stool-based screening test for colon cancer. The stock declined because financial ...Complete Exact Sciences Corp. stock information by Barron's. View real-time EXAS stock price and news, along with industry-best analysis.

Exact Sciences Corp. (EXAS) has a Smart Score of 7 based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom, and Hedge …Web

EXACT SCIENCES CORP ( EXAS) is a large-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...

Source: Third-quarter 2023 earnings slides. Currently, EXAS projects its 2023 revenue to be between $2.48 billion and $2.49 billion. Yet, at its current growth pace, my calculations suggest a more ...Nov 30, 2023 · Exact Sciences Corp EXAS Morningstar Rating Unlock Stock XNAS Rating as of Nov 30, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating... EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission. Find the latest Financials data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com. Exact Sciences (NASDAQ: EXAS) is a biotech stock leveraging AI. The company also comprises the largest holding in Cathie Wood’s ARK Genomic Revolution ETF (BATS: ARKG) at 10.38% total weight.35,260.96. +172.67. 【日本経済新聞】エグザクト・サイエンシズ/EXACT Sciences [EXAS] の株価、チャート、業績推移、会社概要、ニュースなど米国株投資や ...View Our Latest Research Report on EXAS. Exact Sciences Price Performance. Shares of NASDAQ EXAS opened at $67.29 on Tuesday. The stock has a market capitalization of $12.17 billion, a price-to ...Find the latest Institutional Holdings data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.Feb 27, 2018 · ADVISORY, Feb. 27, 2018 (GLOBE NEWSWIRE) -- What: Exact Sciences Corp. (Nasdaq:EXAS), a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer, will open the Nasdaq Stock Market remotely from the Cologuard Classic, a PGA TOUR Champions event in Tucson, Arizona. The last time Exact Sciences (NASDAQ: EXAS) announced its quarterly results, revenue increased 64% compared with the prior-year period. It was a different story on the company's bottom line ...This year, Exact Sciences (NASDAQ: EXAS) expects its revenue will total just under $2.1 billion. That means that in just five years, its top line will have grown by an incredible 683%.

Exscientia Plc American Depositary Shares (EXAI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Shares of Exact Sciences ( EXAS 4.73%) stormed higher by 16.5% over the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain ...A market research report on Exact Sciences ( NASDAQ: EXAS) from Cathie Wood's ARK-Invest ( ARKK) ( ARKG) has caught a lot of attention with another assertive call on the share price performance in ...Instagram:https://instagram. cryptocurrency trading for beginnerspakistan hbl bankmaking money with stock optionsstock market closing dates In the past year, this Zacks Rank #3 (Hold) stock has gained 6.3% against a 9.1% decline of the industry and a 4.7% decline of the S&P 500 composite. The renowned global medical device company has ...Nov 2, 2023 · Nasdaq Composite Stock Market Premium Services. Stock Advisor. Our Flagship Service. ... Exact Sciences (EXAS 4.73%) Q3 2023 Earnings Call Nov 01, 2023, 5:00 p.m. ET. Contents: nvax newscheapest health insurance oklahoma Exact Sciences Corporation (EXAS) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 67.03 +3.03 (+4.73%) At close: 04:00PM EST 67.03 0.00 (0.00%) After hours: 04:03PM EST 1d 5d ucare vs healthpartners EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is ...Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2023 financial results after ...